MycologyWild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods
Introduction
Caspofungin is used clinically in the treatment of invasive candidiasis and in salvage therapy for invasive aspergillosis (IA) (Maertens et al., 2004, Pappas et al., 2009, Walsh et al., 2008). Although breakthrough IA has been reported among patients receiving caspofungin therapy/prophylaxis, thus far, no clinical isolates of Aspergillus spp. have been shown to have acquired the FKS1 mutations considered necessary for echinocandin resistance (Arendrup et al., 2008, Madureira et al., 2007, Rocha et al., 2007). Despite standardization of a broth microdilution (BMD) method for testing caspofungin against Aspergillus spp. (Clinical and Laboratory Standards Institute, 2008, Odds et al., 2004), clinical minimum effective concentration (MEC) breakpoints have not yet been established. Given the increased use of caspofungin and other echinocandins clinically (Arendrup et al., 2008, Neofytos et al., 2009), coupled with the emergence of azole-resistant Aspergillus spp. (Arendrup et al., 2008, Pfaller et al., 2008, Rodriquez-Tudela et al., 2008, Snelders et al., 2008, van der Linder et al., 2009), in vitro surveillance for the emergence of decreased susceptibility to caspofungin among Aspergillus spp. is warranted (Madureira et al., 2007, Rocha et al., 2007). As such, we have conducted global surveillance of Aspergillus spp. using CLSI M38-A2 BMD methods to ascertain the wild-type (WT) MEC distribution for caspofungin and Aspergillus spp. and to establish epidemiologic cutoff values (ECVs) that may be used to assess the emergence of strains with decreased susceptibility to this agent.
Section snippets
Organisms
Between January 2001 and December 2007, 1590 unique patient isolates of Aspergillus spp. (188 Aspergillus flavus, 1187 A. fumigatus, 114 Aspergillus niger, 71 Aspergillus terreus, and 30 Aspergillus versicolor) were obtained from more than 80 medical centers in 24 countries worldwide. Of the submitted isolates, 49% were from centers in North America, 12% from Latin America, 25% from Europe, and 13% from the Asia-Pacific region. The isolates were obtained from a variety of specimen sources,
Results and discussion
The WT MEC distributions for caspofungin and each of the 5 species of Aspergillus are shown in Fig. 1. The modal MECs (percentage of MECs) for caspofungin and each species are as follows (Table 1): A. flavus, 0.015 μg/mL (39.4% of all values); A. fumigatus, 0.015 μg/mL (48.5% of all values); A. niger, 0.007 μg/mL (50.0% of all values); A. terreus, 0.015 μg/mL (38.0% of all values); and A. versicolor, 0.03 μg/mL (33.3% of all values). The modal MEC ± one 2-fold dilution encompassed 92.6% of all
Acknowledgments
The authors thank Caitlin Howard for excellent secretarial support.
This study was supported in part by research and educational grants from Astellas US (Deerfield, IL), Merck (Whitehouse Station, NJ), and Pfizer Pharmaceuticals (New York, NY).
References (21)
- et al.
Breakthrough invasive aspergillosis in allogenic haematopoietic stem cell transplant recipients treated with caspofungin
Int. J. Antimicrob. Agents
(2007) Resistance to echinocandin-class antifungal drugs
Drug Resist. Updat.
(2007)- et al.
Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
Clin. Microbiol. Infect.
(2006) - et al.
Establishing in vitro–in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins
Antimicrob. Agents Chemother.
(2008) - et al.
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients
Cancer
(2006) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard - second edition, M38-A2
(2008)- et al.
Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin
Med. Mycol.
(2005) - et al.
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
J. Antimicrob. Chemother.
(2003) - et al.
Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction β-d-1,3 glucan levels in culture
Antimicrob. Agents Chemother.
(2006) - et al.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
Clin. Infect. Dis.
(2004)